Biocon Ltd. — Capital/Financing Update 2021

Jul 15, 2021

==> picture [132 x 53] intentionally omitted <==

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423

July 15, 2021

CIN : L24234KA1978PLC003417

www.biocon.com

	www.biocon.com
To, The Manager BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street,Mumbai – 400 001	To, The Manager National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex, Mumbai – 400 050
Scrip Code- 532523	Scrip Symbol- Biocon

Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/ Madam,

In continuation to our letter dated November 7, 2020, wherein it was intimated that Biocon Limited (the ‘ Company ’), Biocon Biologics Limited (‘ BBL ’), and Goldman Sachs India AIF Scheme - 1 and 2, schemes setup under Goldman Sachs India Alternative Investment Trust, acting through its investment manager, Goldman Sachs (India) Alternative Investment Management Private Limited ( the ‘Investor’) had executed a Securities Subscription Agreement dated November 7, 2020 (‘ SSA ’) and in continuation to our letter dated January 7, 2021, wherein it was intimated that the Company, BBL, the Investor, Tata Capital Growth Fund II, Activ Pine LLP and Beta Oryx Limited (collectively with the Investor, the Existing Investors ) had executed a Shareholders’ Agreement dated January 7, 2021 (‘ SHA’ ) (SSA together with the SHA, hereinafter called as ‘ Transaction Documents’ ).

In this regard, please note that the Transaction Documents have been amended with effect from July 14, 2021. Details of amendment and impact thereof is provided in Annexure A.

This intimation is being made in compliance with Regulations 30, read with Schedule III and other applicable regulations of the SEBI Listing Regulations and the required disclosure is enclosed as Annexure A.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking you,

Yours faithfully,

For Biocon Limited

MAYANK Digitally signed by MAYANK VERMA VERMA Date: 2021.07.15 15:32:25 +05'30'

---

Mayank Verma

Company Secretary and Compliance Officer Enclosed: Annexure A

ANNEXURE A

The details as required under SEBI Listing Regulations read with SEBI Circular No. CIR/CFO/CMD/4/2015 dated September 9, 2015 are as under: -

In case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s):

S. No.	Particulars	Details
1.	Name of parties to the agreement	The Transaction Documents have been executed between the Company, BBL, the Existing Investors and Goldman Sachs India Alternative Investment Trust AIF Scheme – 1 and 2 , schemes setup under Goldman Sachs India Alternative Investment Trust, acting through its investment manager, Goldman Sachs (India) Alternative Investment Management Private Limited (the ‘Investor’)*.
2.	Nature of the agreement	Amendment agreements to the SSA and the SHA.
3.	Date of execution of the agreement	Original Execution Date of SSA: November 7, 2020 Original Execution Date of SHA: January 7, 2021 Amendment effective Date: July 14, 2021
4.	Details of amendment and impact thereof or reasons of termination and impact thereof.	The amendment to the SSA,inter alia_records the amendment of certain definitions in relation to the redemption amount payable by BBL under the SSA, while the amendment to the SHA,_inter alia, updates a covenant applicable to BBL, in relation to maintenance of external net debt.

*The Investor transferred a part of its securities held in BBL to GS Scheme 2 on June 10, 2021.